A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 921e0ba62c1c6464-LAX IP: 118.31.43.22 UTC time: 2025-03-17T17:00:15+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4

View original article

GYNECOLOGIC ONCOLOGY

Like

Share Bookmark

0 0 0 0 0 0 0

More from this channel

A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study

Comments (0)